Goldman Sachs Group Inc Adc Therapeutics Sa Transaction History

Goldman Sachs Group Inc

  • $613 Billion
  • Q4 2024

A detailed history of Goldman Sachs Group Inc transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,673,177 shares of ADCT stock, worth $2.68 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,673,177
Previous 1,688,594 0.91%
Holding current value
$2.68 Million
Previous $5.32 Million 37.41%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 11, 2025
SELL
$1.89 - $3.48 $29,138 - $53,651
-15,417 Reduced 0.91%
1,673,177 $3.33 Million
Q3 2024

Nov 14, 2024
BUY
$2.59 - $4.01 $424,441 - $657,146
163,877 Added 10.75%
1,688,594 $5.32 Million
Q2 2024

Aug 13, 2024
SELL
$2.55 - $5.09 $40,269 - $80,381
-15,792 Reduced 1.03%
1,524,717 $4.82 Million
Q1 2024

May 15, 2024
BUY
$1.66 - $5.29 $134,451 - $428,463
80,995 Added 5.55%
1,540,509 $6.92 Million
Q4 2023

Feb 13, 2024
BUY
$0.47 - $1.79 $191,071 - $727,699
406,536 Added 38.61%
1,459,514 $2.42 Million
Q3 2023

May 14, 2024
SELL
$0.72 - $2.37 $292,705 - $963,490
-406,536 Reduced 27.85%
1,052,978 $947,000
Q3 2023

Nov 14, 2023
SELL
$0.72 - $2.37 $60,919 - $200,528
-84,611 Reduced 7.44%
1,052,978 $947,000
Q2 2023

May 14, 2024
SELL
$1.9 - $2.66 $2.31 Million - $3.23 Million
-1,216,116 Reduced 51.67%
1,137,589 $2.45 Million
Q2 2023

Aug 14, 2023
SELL
$1.9 - $2.66 $2.31 Million - $3.23 Million
-1,216,116 Reduced 51.67%
1,137,589 $2.45 Million
Q1 2023

May 14, 2024
BUY
$1.92 - $5.45 $369,310 - $1.05 Million
192,349 Added 8.9%
2,353,705 $4.59 Million
Q1 2023

May 11, 2023
BUY
$1.92 - $5.45 $369,310 - $1.05 Million
192,349 Added 8.9%
2,353,705 $4.59 Million
Q4 2022

May 14, 2024
BUY
$2.87 - $5.24 $6.12 Million - $11.2 Million
2,132,701 Added 7442.68%
2,161,356 $8.3 Million
Q4 2022

Feb 13, 2023
BUY
$2.87 - $5.24 $6.12 Million - $11.2 Million
2,132,701 Added 7442.68%
2,161,356 $8.3 Million
Q3 2022

May 14, 2024
SELL
$4.66 - $10.31 $6.67 Million - $14.8 Million
-1,430,859 Reduced 98.04%
28,655 $138,000
Q3 2022

Nov 10, 2022
BUY
$4.66 - $10.31 $133,532 - $295,433
28,655 New
28,655 $138,000

Others Institutions Holding ADCT

# of Institutions
85
Shares Held
53.5M
Call Options Held
28K
Put Options Held
60.4K
View Full List

About ADC Therapeutics SA

ADCT Quotes by TradingView
  • Ticker ADCT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,645,296
  • Market Cap $124M
  • Description
  • ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...
More about ADCT
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email